Inotek Pharmaceuticals Corporation to Expand Phase 2 Clinical Trial in Glaucoma Based on Promising Preliminary Results
7/21/2011 10:25:48 AM
LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corp., a leader in the development of innovative medicines to address significant diseases of the eye, today announced that the Company has successfully completed the first two of three stages of a multiple-dose Phase 2b clinical trial of its novel eye-drop candidate, INO-8875, in patients with glaucoma or ocular hypertension. Based on the achievement of this milestone, Inotek’s investors have committed the final tranche of their previous $20 million funding round and have committed an additional $3.7 million to expand the final portion of the ongoing clinical trial by increasing the number of subjects and the duration of treatment in the final phase.
comments powered by